Imidazoles

Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex™ 4 mcg/ mL

Retrieved on: 
Tuesday, December 10, 2019
Imidazoles, Drugs, Veterinary drugs, Anxiolytics, Dexmedetomidine, Medetomidine, Chemistry, Physical sciences

PRINCETON, N.J., Dec. 10, 2019 /PRNewswire/ --Slayback Pharma LLC announced today the final approval and launch in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection.

Key Points: 
  • PRINCETON, N.J., Dec. 10, 2019 /PRNewswire/ --Slayback Pharma LLC announced today the final approval and launch in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection.
  • Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, and can be ordered through your wholesaler/distributor.
  • Due to the known pharmacological effects of dexmedetomidine hydrochloride in 0.9% sodium chloride injection, patients should be continuously monitored while receiving dexmedetomidine hydrochloride in 0.9% sodium chloride injection.
  • Some patients receiving dexmedetomidine hydrochloride in 0.9% sodium chloride injection have been observed to be arousable and alert when stimulated.

Kura Oncology to Participate in Piper Jaffray Healthcare Conference

Retrieved on: 
Tuesday, November 26, 2019
Life sciences, Articles, Biotechnology, Specialty drugs, Chloroarenes, Imidazoles, Tipifarnib, Biopharmaceutical, Oncology

SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 12:00 p.m.

Key Points: 
  • SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 12:00 p.m.
  • The conference will be held December 3-5, 2019 in New York City.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications.

TCDI® Announces Janet Hamilton as Director of Legal Process

Retrieved on: 
Tuesday, November 19, 2019
Recruitment, Practice of law, Imidazoles, Thiocarbonyldiimidazole, Thioureas, Law firm, Articles

GREENSBORO, N.C., Nov. 19, 2019 /PRNewswire/ --Technology Concepts & Design, Inc. (TCDI), a pioneer in legal technology, welcomes Janet Hamilton as director of legal process.

Key Points: 
  • GREENSBORO, N.C., Nov. 19, 2019 /PRNewswire/ --Technology Concepts & Design, Inc. (TCDI), a pioneer in legal technology, welcomes Janet Hamilton as director of legal process.
  • Hamilton brings over 20 years of recruitment experience within the legal industry.
  • "We are thrilled to bring someone onboard with the years of recruitment and team development experience that Janet brings to TCDI," said Chief Legal Process Officer, Caragh Landry.
  • For 30 years, TCDI has been a pioneer in the legal market empowering law firms and corporations to secure, discover, analyze and defend critical data.

Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019
Health, Life sciences, Medical specialties, Non-Hodgkin lymphoma, RTT, Chloroarenes, Imidazoles, Tipifarnib, American Society of Hematology, Oncology, Lymphoma, T-cell lymphoma

SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Companys lead drug candidate, tipifarnib, has been accepted for oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held from December 7-10, 2019 in Orlando.

Key Points: 
  • SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Companys lead drug candidate, tipifarnib, has been accepted for oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held from December 7-10, 2019 in Orlando.
  • The following abstract was published today and is now available on the ASH website at www.hematology.org .
  • Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Novel Therapies in Peripheral T-cell Lymphomas
    A copy of the presentation will be available on Kura's website at www.kuraoncology.com following presentation at the meeting.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

Retrieved on: 
Tuesday, October 29, 2019
Chloroarenes, Imidazoles, Tipifarnib, European Organisation for Research and Treatment of Cancer, HRAS, Health, Ras GTPase, Oncology, Medicine, Branches of biology

The results are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Key Points: 
  • The results are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
  • An analysis of preliminary data from the RUN-HN trial performed in October 2018 showed a significant association between tumor HRAS mutant allele frequency and clinical benefit from tipifarnib.
  • Based upon these observations, Kura introduced a minimum HRAS mutant variant allele frequency as an entry criterion prior to the initiation of its registration-directed trial of tipifarnib in HRAS mutant HNSCC (AIM-HN) in November 2018.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 23, 2019
Chloroarenes, Imidazoles, Tipifarnib, Academic conferences, Head and neck cancer, Knowledge, HRAS, Poster session

Nearly 500 abstracts were considered for this years program and just 10 were selected as short-talks by the Scientific Committee Cochairs.

Key Points: 
  • Nearly 500 abstracts were considered for this years program and just 10 were selected as short-talks by the Scientific Committee Cochairs.
  • As a result of the selection, the previously announced poster presentation related to the Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC has been rescheduled to take place following the oral presentation.
  • A copy of the oral and poster presentations will be available at www.kuraoncology.com following presentation at the meeting.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 16, 2019
Life sciences, Articles, Biotechnology, Chloroarenes, Imidazoles, Tipifarnib, Biopharmaceutical

Details are as follows:

Key Points: 
  • Details are as follows:
    The abstract has been selected as a newsworthy candidate for the meetings official press program and will be embargoed until 11:00 a.m.
  • A copy of the poster will be available at www.kuraoncology.com following presentation at the meeting.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications.

Cell Journals Publishes BeyondSpring’s New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation

Retrieved on: 
Tuesday, October 8, 2019
Chemistry, Diketopiperazines, Imidazoles, Cytoskeleton, Plinabulin, Proteins, Branches of biology, Tubulin

Researchers noted that, in cancer patients, high expression of the GEF-H1 immune gene signature is associated with prolonged survival.

Key Points: 
  • Researchers noted that, in cancer patients, high expression of the GEF-H1 immune gene signature is associated with prolonged survival.
  • Plinabulin is among the most potent tubulin targeted agents for maturing DCs.
  • This finding significantly contributes towards BeyondSprings understanding of the durable anti-cancer effects demonstrated to date in nonclinical and clinical testing with Plinabulin.
  • Plinabulin, BeyondSprings lead asset, is a marine-derived small molecule that sequesters tubulin heterodimers in a differentiated manner from other agents in this class.

Denise Bach joins TCDI® as Senior Director of Legal Services

Retrieved on: 
Friday, September 27, 2019
Musical instruments, Music, Imidazoles, Thiocarbonyldiimidazole, Thioureas, Johann Sebastian Bach, Business process management, Greensboro, North Carolina

GREENSBORO, N.C., Sept. 27, 2019 /PRNewswire/ -- Technology Concepts & Design, Inc. (TCDI), a pioneer in legal technology, welcomes Denise Bach as Senior Director of Legal Services.

Key Points: 
  • GREENSBORO, N.C., Sept. 27, 2019 /PRNewswire/ -- Technology Concepts & Design, Inc. (TCDI), a pioneer in legal technology, welcomes Denise Bach as Senior Director of Legal Services.
  • Bach brings with her 25 years of experience in the legal industry.
  • "Denise has a deep understanding of the legal process and the significant role technology plays in that process," said TCDI CEO Bill Johnson.
  • TCDI has a great reputation in the legal services industry," said Bach.

BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices

Retrieved on: 
Wednesday, September 18, 2019
Anxiolytics, Dexmedetomidine, Imidazoles, Agitation, Adrenergic, Branches of biology, Chemistry, Neuroscience

BioXcel Therapeutics plans to conduct a feasibility study with potential applications for uses in commercially available wearable digital devices to measure nervous and motor system activity relevant to both agitation and the mechanism of action of the Companys drug candidate, BXCL501.

Key Points: 
  • BioXcel Therapeutics plans to conduct a feasibility study with potential applications for uses in commercially available wearable digital devices to measure nervous and motor system activity relevant to both agitation and the mechanism of action of the Companys drug candidate, BXCL501.
  • There are no predictive technologies for agitation and FDA approved treatments to help the agitation associated with Alzheimers disease or other forms of dementia.
  • BioXcel Therapeutics is very pleased to further develop the BXCL501 program with integrated preventive treatment approaches, said Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics.
  • BXCL501 is an investigational, proprietary sublingual thin film of dexmedetomidine, a selective alpha2 A -adrenergic agonist designed for the treatment of acute agitation.